Yes, in the next few months, writes a confident David Risinger, a Merrill Lynch drug-industry analyst, in an investor note today.

You’ll recall that Wyeth, which is almost as famous for serious and repeated manufacturing violations as the fen-phen diet pills scandal, is struggling to get an FDA blessing for its plant in Guayama, Puerto Rico. Without it, the drugmaker can’t get some new meds to market.

“We are not just counting on Wyeth,” writes Risinger. “We are also encouraged that Wyeth hired Lachman, who is viewed to be among the best manufacturing consulting firms in the business last year, and that firm said Wyeth was ready for re-inspection in January.”

The FDA, he adds, is currently re-inspecting the facility and will likely provide feedback to Wyeth in March. The FDA may want to include a recommendation for a managerial overhaul. [tags]FDA, Lachman, Puerto Rico, Wyeth[/tags]